Philadelphia University + Thomas Jefferson University
Institute of Emerging Health Professions
Lambert Center for the Study of Medicinal Cannabis & Hemp

News & Events

Lambert Center Media Coverage

Up-to-date Steering Committee Article Citations

Eiden RD,… Huestis MA. Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. Neurotox Teratol. 2018; 68:47-56.

Carlier J,…Huestis MA. Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. J Pharmaceutical Biomed Anal. 2018; 157:27-35.

Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med. 2018; 178: 679-80.

Conchiero M, Huestis MA. Drug exposure during pregnancy: Analytical methods and toxicological findings. Bioanalysis. 2018; 10:587-606.

Schelienz NJ, …Vandrey R.  The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018; 187:254-60.

Sempio C,… Huestis MA. Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Test Anal. 2018; 10:518-529.

DePhilippis D, Petry NM, Bonn-Miller MO, et al. The national implementation of Contingency Management (CM) in the Department of Veterans Affairs: Attendance at CM sessions and substance use outcomes. Drug Alcohol Depend. 2018; 185:367-73.

Logan BK, … Huestis MA. Recommendations for toxicological investigation of drug-impaired driving and motor vehicle fatalities-2017 update.  J Analytic Toxicol. 2018; 42:63-68.

George TP, Hill KP, Vaccarino FJ. Cannabis legalization and psychiatric disorders: Caveat “Hemp-tor”. Can J Psychiatr. 2018; https://doi.org/10.1177/0706743718762387.

Abrams, Donald I. (2018) "The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report, European Journal of Internal Medicine,
Vol. 49 Available at: https://doi.org/10.1016/j.ejim.2018.01.003.

Pollack, Charles V. Jr, MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP and Clark, Kate MPA (2017) "A Center Cultivating Cannabis Research and Policy take Root at Jefferson," Population Health Matters (Formerly Health Policy Newsletter): Vol. 30 : Iss. 4 , Article 7.
Available at: http://jdc.jefferson.edu/hpn/vol30/iss4/7

Galal Osman A,  Elokely KM, Yadav VK,… ElSohly MA. Bioactive products from singlet oxygen photooxygenation of cannabinoids. Eur J Medicinal Chem. 2018; 143:983-96.

Mateo Y, Johnson KA, Covey DP, … Guzman M, et al. Endocannabinoid actions on cortical terminals orchestrate local modulation of dopamine release in the nucleus accumbens. Neuron. 2017; 96:1112-1126.e5

Hill KP, Palastro MD. Medical cannabis for the treatment of chronic pain and other disorders: Misconceptions and facts. Pol Arch Intern Med. 2017; 127: 785-789.

Hill KP, Palastro MD, Gruber SA et al. Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. Am J Addict. 2017; 26:795-801.

Raslan AE, Radwan MM,Ahmed SA,…ElSohly MA. Monanchoramides A–D, ceramides from the marine sponge Monanchora clathrata with cytotoxic activity. Phytochem Lett. 2018; 23:83-89.

Bonn-Miller MO, Loflin MJ, Thomas BF,… Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017; 318:718-9.

Díaz-Alonso J, De Salas-Quiroga A, Paraíso-Luna J,… Guzmán, M, et al. Loss of Cannabinoid CB1 Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. Cerebral Cortex.2017; 27:5303-17.


News & Events Archive

April 4, 2018

Spinal Cord Injury and Cannabis Program

We are now supporting a spinal cord injury and cannabis program developed  by Dr. Dan Graves and his team at the Dep’t of Rehabilitation Medicine.

This project is a three-part approach to providing a foundation for cannabis clinical trials. This proposal combines the long history of the Department of Rehabilitation Medicine and the expertise of the Lambert Center to systematically prepare a foundation for the conduct of clinical trials. Chronic neuropathic pain is a condition experienced by a majority of patients with SCI. However, the research environment for the study of cannabis in SCI is limited. The three sections of this proposal will provide a solid foundation on which to build these trials.

1) The Consumer Training in Research Ethics and Scientific Information on Medical Applications of Cannabis had it first meeting on March 20, 2018, to integrate the patient voice into research design. A selected group of patients with SCI attended this training, which will become an integral component of future research.

2)  The large survey of knowledge, experience and attitudes concerning cannabis will inform the research team as to the issues that need to be addressed in recruitment and conduct clinical trials.

3) The final component will be an in depth investigation of the differences in physical health, quality of life, community participation and cognition in self-selected groups of current cannabis users, past cannabis users and non-cannabis users. This will provide needed information for the research team to select possible research questions and potential outcome measures.

For more information contact us at IEHP-info@jefferson.edu

May 2, 2017

Ex-NFL Players Attend Lambert Center Meeting to Discuss Medical Marijuana

During a three-day summit at the Union League of Philadelphia, attendees of various backgrounds from around the world gathered to discuss medical marijuana.  Three former NFL players and one former NHL player joined on the second day of the summit.  Players in attendance were Todd Herremans, former offensive lineman for the Eagles; Lance Johnston, former defensive end for the Oakland Raiders and Minnesota Vikings; Marques Colston, former wide receiver for New Orleans Saints; and Riley Cote, hemp advocate and once an enforcer for the Flyers.

Watch Dr. Charles Pollack's interview with Philly.com here.


March 30, 2017

Dr. Charles Pollack Discusses Cannabis as Medicine with GreenSea Distribution

Read full interview here


February 22, 2017

Lambert Center Entrepreneurship & Social Impact Initiative Member, Lindy Snider, Invests in Medical Marijuana

Lindy Snider, whose late father, Ed Snider, benefited from medical cannabis when he had metastatic bladder cancer, is dully supporting the shift in Pennsylvania's medical marijuana industry.  During the last few months of her father's life, his appetite dwindled but cannabis soon restored that.  

Along with being a member of the Entrepreneurship and Social Impact Initiative for The Lambert Center, Snider has a startup called Lindi Skin (skin care products for cancer patients) and serves on the board for KindFinancial (cannabis industry banking).  

Snider's goal is to build a 125,000-square-foot cannabis growing facility near the Bucks County line that would employ up to 50 people.  If the Pennsylvania Department of Health accepts her application, which is due by March 20th, marijuana production would begin in 2018.  Snider has been deemed a front-runner in a pool of about 800 applicants. 

See the full article here.


December 22, 2016

Jefferson Receives $1.5 Million from Six Organizations to Support Cannabis Research & Education

The Lambert Center for the Study of Medicinal Cannabis and Hemp, funded entirely through philanthropy, has received a combined $1.5 million from six Pennsylvania organizations.

“We are recognizing these organizations as our ‘Founding Supporters’, because these gifts are enabling us to build the research infrastructure of The Lambert Center,” said Charles V. Pollack Jr., MA, MD, Director of Jefferson’s Institute of Emerging Health Professions. “We are very grateful for this cascade of generosity. It’s a strong vote of confidence in this unique academic endeavor.” 

The initial six Founding Supporters are: The Tuttleman Family Foundation, PharmaCannis, PA Options for Wellness, Commonwealth Alternative Medicinal Options, Keystone Wellness Research Fund, LLC, and Oha Wellness.

This support will drive educational initiatives and unbiased medical cannabis research.

Read the full press release here.


Barry Lambert

December 7, 2016

IEHP receives $3 Million from Australian Philanthropist, Barry Lambert

The Center of Cannabis Research and Education (CMCER) has been renamed to The Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University.

Barry Lambert, 70, is renowned in the Australian banking industry for founding Count Financial, Australia’s largest network of accounting-based advisory firms. It was the love only a grandparent can feel that inspired the Lamberts’ philanthropy. As an infant, Barry and Joy’s granddaughter, Katelyn, was diagnosed with Dravet’s syndrome, a rare genetic abnormality that affects the brain's electric signaling system and causes severe and repetitive seizures. Medical cannabis has been shown to be one of the few therapies that mitigates the seizures caused by the condition, and cannabis derived from hemp indeed gave Katelyn substantial relief. The Lamberts’ gift reflects a belief that more study into medicinal cannabis will offer greater hope for others with this and other diverse conditions. Read more from the press release here.

For more media coverage:

Philadelphia Magazine
Philadelphia Business Journal
Philly Voice
Philadelphia Inquirer


October 28-30, 2016

Carolina Cannabinoid Collaborative Conference

Temple’s Lewis Katz School of Medicine and its Center for Substance Abuse Research and The Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University (LCSMCH) will be co-presenting the 2016 Carolina Cannabinoid Collaborative Conference on October 28th-30th. Over 100 of the country’s leading cannabinoid researchers will gather here in Philadelphia to address recent developments and discoveries. The Conference will feature Keynote speakers, Donald Abrams, MD, Chief of Hematology-Oncology at Zuckerberg San Francisco General Hospital, a member of LCSMCH’s international Academic Steering Committee, and Yasmin Hurd, PhD, Professor of Psychiatry, Neuroscience and Pharmacology and Systems Therapeutics, and Director of the Center for Addictive Disorders at the Icahn School of Medicine at Mount Sinai.  

Read the press release here.